The Foundation for Investigating Factor XI As a Target for Inhibition in Human Cardiovascular Disease

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2024 Apr 25

PMID 38662114

Authors

Ahmed E Ali

Richard C Becker

Affiliations

Soon will be listed here.

Abstract

Anticoagulant therapy is a mainstay in the management of patients with cardiovascular disease and related conditions characterized by a heightened risk for thrombosis. Acute coronary syndrome, chronic coronary syndrome, ischemic stroke, and atrial fibrillation are the most common. In addition to their proclivity for thrombosis, each of these four conditions is also characterized by local and systemic inflammation, endothelial/endocardial injury and dysfunction, oxidative stress, impaired tissue-level reparative capabilities, and immune dysregulation that plays a critical role in linking molecular events, environmental triggers, and phenotypic expressions. Knowing that cardiovascular disease and thrombosis are complex and dynamic, can the scientific community identify a common pathway or specific point of interface susceptible to pharmacological inhibition or alteration that is likely to be safe and effective? The contact factors of coagulation may represent the proverbial "sweet spot" and are worthy of investigation. The following review provides a summary of the fundamental biochemistry of factor XI, its biological activity in thrombosis, inflammation, and angiogenesis, new targeting drugs, and a pragmatic approach to managing hemostatic requirements in clinical trials and possibly day-to-day patient care in the future.

References

Gailani D, Broze Jr G . Factor XI activation in a revised model of blood coagulation. Science. 1991; 253(5022):909-12. DOI: 10.1126/science.1652157. View

Cheng Q, Tucker E, Pine M, Sisler I, Matafonov A, Sun M . A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010; 116(19):3981-9. PMC: 2981546. DOI: 10.1182/blood-2010-02-270918. View

Bouma B, Griffin J . Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem. 1977; 252(18):6432-7. View

McMullen B, Fujikawa K, Davie E . Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains. Biochemistry. 1991; 30(8):2056-60. DOI: 10.1021/bi00222a008. View

Walsh P, Sinha D, Koshy A, Seaman F, Bradford H . Functional characterization of platelet-bound factor XIa: retention of factor XIa activity on the platelet surface. Blood. 1986; 68(1):225-30. View

Doolittle R . Step-by-step evolution of vertebrate blood coagulation. Cold Spring Harb Symp Quant Biol. 2009; 74:35-40. DOI: 10.1101/sqb.2009.74.001. View

Podmore A, Smith M, Savidge G, Alhaq A . Real-time quantitative PCR analysis of factor XI mRNA variants in human platelets. J Thromb Haemost. 2004; 2(10):1713-9. DOI: 10.1111/j.1538-7836.2004.00924.x. View

Zhang X, Lewandowska M, Aldridge M, Iglay K, Wolford E, Shapiro A . Global epidemiology of factor XI deficiency: A targeted review of the literature and foundation reports. Haemophilia. 2022; 29(2):423-434. DOI: 10.1111/hae.14687. View

Maas C, Renne T . Coagulation factor XII in thrombosis and inflammation. Blood. 2018; 131(17):1903-1909. DOI: 10.1182/blood-2017-04-569111. View

10.

Gruber A, Hanson S . Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood. 2003; 102(3):953-5. DOI: 10.1182/blood-2003-01-0324. View

11.

Puy C, Tucker E, Matafonov A, Cheng Q, Zientek K, Gailani D . Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor. Blood. 2015; 125(9):1488-96. PMC: 4342360. DOI: 10.1182/blood-2014-10-604587. View

12.

Yun T, Baglia F, Myles T, Navaneetham D, Lopez J, Walsh P . Thrombin activation of factor XI on activated platelets requires the interaction of factor XI and platelet glycoprotein Ib alpha with thrombin anion-binding exosites I and II, respectively. J Biol Chem. 2007; 282(39):29067. DOI: 10.1016/S0021-9258(20)58642-0. View

13.

Nieuwland R, Gardiner C, Dignat-George F, Mullier F, Mackman N, Woodhams B . Toward standardization of assays measuring extracellular vesicle-associated tissue factor activity. J Thromb Haemost. 2019; 17(8):1261-1264. PMC: 6851965. DOI: 10.1111/jth.14481. View

14.

Greengard J, Heeb M, Ersdal E, Walsh P, Griffin J . Binding of coagulation factor XI to washed human platelets. Biochemistry. 1986; 25(13):3884-90. DOI: 10.1021/bi00361a022. View

15.

Miller T, Sinha D, Baird T, Walsh P . A catalytic domain exosite (Cys527-Cys542) in factor XIa mediates binding to a site on activated platelets. Biochemistry. 2007; 46(50):14450-60. PMC: 2532527. DOI: 10.1021/bi701310x. View

16.

Fogelson A, Hussain Y, Leiderman K . Blood clot formation under flow: the importance of factor XI depends strongly on platelet count. Biophys J. 2012; 102(1):10-8. PMC: 3250692. DOI: 10.1016/j.bpj.2011.10.048. View

17.

Humphreys S, Whyte C, Mutch N . "Super" SERPINs-A stabilizing force against fibrinolysis in thromboinflammatory conditions. Front Cardiovasc Med. 2023; 10:1146833. PMC: 10155837. DOI: 10.3389/fcvm.2023.1146833. View

18.

Drake T, Morrissey J, Edgington T . Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989; 134(5):1087-97. PMC: 1879887. View

19.

Mackman N . Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004; 24(6):1015-22. DOI: 10.1161/01.ATV.0000130465.23430.74. View

20.

Nakazawa F, Kannemeier C, Shibamiya A, Song Y, Tzima E, Schubert U . Extracellular RNA is a natural cofactor for the (auto-)activation of Factor VII-activating protease (FSAP). Biochem J. 2005; 385(Pt 3):831-8. PMC: 1134760. DOI: 10.1042/BJ20041021. View